VG Life Sciences Inc (VRALD) USD0.0001
VG Life Sciences Inc. is a biotechnology company. The Company is engaged in developing transformative therapies to treat drug-resistant cancers, infectious diseases and autoimmune diseases caused by chronic inflammation. The Company operates as a drug discovery and development company researching two core technologies: Targeted Peptide Technology (TPT) and Metabolic Disruption Technology (MDT). The Company's MDT compounds impede tumor cells' ability to meet their energy requirements, leaving cancer cells vulnerable to cancer-killing agents. Its autoimmune therapy, TPT, eliminates a subpopulation of pro-inflammatory immune cells and presents a possible treatment for autoimmune and infectious diseases. Its peptides are designed to function in all Major Histocompatibility Complex II (MHC-II) phenotypes. It also has a drug research program in pre-clinical stages, a TPT therapy for human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) using VG1177.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.